Insulin resistance in patients with depression and its changes in the clinical course of depression: A report on three cases using the minimal model analysis

Internal Medicine

Volumn 38, Issue 3, 1999, Pages 257-260

  Okamura, Fumio ^a   Tashiro, Atsushi ^a   Utsumi, Atsushi ^a   Imai, Towako ^a   Suchi, Takatoshi ^a   Hongo, Michio ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hyper insulin response; Insulin sensitivity; Intravenous glucose tolerance test; Oral glucose tolerance test (OGTT)

Indexed keywords

ANTIDEPRESSANT AGENT;

ADULT; ANALYTIC METHOD; ARTICLE; BODY WEIGHT; CASE REPORT; DEPRESSION; GLUCAGON BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; ORAL GLUCOSE TOLERANCE TEST;

EID: 0033022919     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.38.257     Document Type: Article

References (31)

1. Gavard JA, Lustman PJ, Clouse RE. Prevalance of depression in adults with diabetes. An epidemiological evaluation. Diabetes Care 16: 1167-1178, 1993.
2. Eaton WW, Armenian H, Gallo J, Pratt L, Ford DE. Depression and risk for onset of type II diabetes. A prospective population-based study. Diabetes Care 19: 1097-1102, 1996.
3. Winokur A, Maislin G, Phillips JL, Amsterdam JD. Insulin resistance after oral glucose tolerance testing in patients with major depression. Am J Psychiatry 145: 325-330, 1988.
4. Tashiro A, Hongo M, Ota R, Utsumi A, Imai T. Hyper-insulin response in a patient with depression. Changes in insulin resistance during recovery from depression. Diabetes Care 20: 1924-1925, 1997 (letter).
5. Nathan RS, Sachar EJ, Asnis GM, Halbreich U, Halpern FS. Relative insulin insensitivity and cortisol secretion in depressed patients. Psychiatry Res 4: 291-300, 1981.
6. Finegood DT, Hramiak IM, Dupre J. A modified protocol for estimation of insulin sensitivity with the minimal model of glucose kinetics in patients with insulin-dependent diabetes. J Clin Endocrinol Metab 70: 1538-1549, 1990.
7. Bergman RN. Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes 38: 1512-1527, 1989.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC, Americal Psychiatric Association, 1994, pp. 213-233.
9. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62, 1960.
10. Walton C, Godsland IF, Proudler AJ, Felton CV, Wynn V. Effect of body mass index and fat distribution on insulin sensitivity, secretion, and clearance in nonobese healthy men. J Clin Endocrinol Metab 75: 170-175, 1992.
11. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42: 1663-1672, 1993.
12. Ferrannini E, Vichi S, Beck-Nielsen H, Laakso M, Paolisso G, Smith U, and European Group for the Study of Insulin Resistance (EGIR). Insulin action and age. Diabetes 45: 947-953, 1996.
13. Devlin JT. Effects of exercise on insulin sensitivity in humans. Diabetes Care 15: 1690-1693, 1992.
14. Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: a comparison study of four medications. Psychiatry Res 26: 265-271, 1988.
15. Berken GH, Weinstein DO, Stern WC. Weight gain. A side-effect of tricyclic antidepressants. J Affect Disord 7: 133-138, 1984.
16. Harris B, Young J, Hughes B. Changes occurring in appetite and weight during short-term antidepressant treatment. Br J Psychiatry 145: 645-648, 1984.
17. Goodnick PJ, Henry JH, Buki VM. Treatment of depression in patients with diabetes mellitus. J Clin Psychiatry 56: 128-136, 1995 (see comments).
18. Marley J, Rohan A. Mianserin-induced hyperglycaemia. Lancet 342: 1430-1431, 1993 (letter).
19. Lustman PJ, Griffith LS, Clouse RE, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med 59: 241-250, 1997.
20. Musselman DL, Nemeroff CB. Depression and endocrine disorders: focus on the thyroid and adrenal system. Br J Psychiatry Suppl 30: 123-128, 1996.
21. Targum SD, Sullivan AC, Byrnes SM. Neuroendocrine interrelationships in major depressive disorder. Am J Psychiatry 139: 282-286, 1982.
22. Krishnan KR, Manepalli AN, Ritchie JC, et al. Growth hormone-releasing factor stimulation test in depression. Am J Psychiatry 145: 90-92, 1988.
23. Cohen SI. Cushing's syndrome: a psychiatric study of 29 patients. Br J Psychiatry 136: 120-124, 1980.
24. Jeffcoate WJ, Silverstone JT, Edwards CR, Besser GM. Psychiatric manifestations of Cushing's syndrome: response to lowering of plasma cortisol. Q J Med 48: 465-472, 1979.
25. Kelly WF. Psychiatric aspects of Cushing's syndrome. Q J Med 89: 543-551, 1996.
26. Starkman MN, Schteingart DE, Schork MA. Depressed mood and other psychiatric manifestations of Cushing's syndrome: relationship to hormone levels. Psychosom Med 43: 3-18, 1981.
27. Meltzer H. Serotonergic dysfunction in depression. Br J Psychiatry Suppl 8: 25-31, 1989.
28. Grahame-Smith DG. Serotonin function in affective disorders. Acta Psychiatr Scand Suppl 350: 7-12, 1989.
29. Coppen AJ, Doogan DP. Serotonin and its place in the pathogenesis of depression. J Clin Psychiatry 49 Suppl: 4-11, 1988.
30. Maheux P, Ducros F, Bourque J, Garon J, Chiasson JL. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord 21: 97-102, 1997.
31. Breum L, Bjerre U, Bak JF, Jacobsen S, Astrup A. Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism 44: 1570-1576, 1995.